Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Abroad (travel likely)RecruitingPHASE1, PHASE2
Conditions
Acute Myeloid Leukemia · Blasts 20 Percent or More of Bone Marrow Nucleated Cells · High Risk Myelodysplastic Syndrome · Recurrent Acute Biphenotypic Leukemia · Recurrent Acute Myeloid Leukemia · Recurrent High Risk Myelodysplastic Syndrome · Refractory Acute Myeloid Leukemia · Refractory High Risk Myelodysplastic Syndrome
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
M D Anderson Cancer Center, Houston, Texas, United States
Contact: Principal Investigator (Musa Yilmaz)
Study leads
Musa Yilmaz
Principal Investigator
M.D. Anderson Cancer Center